Weekend Funding Roundup:
Apr 6, 2026
Easter weekend with a countdown. Precision oncology startup Stipple Bio emerged from stealth with $100M. Brain health AI company Beacon Biosignals extended its Series B to $97M. But the real story is the clock: Trump set a Tuesday 8 PM ultimatum for Iran to reopen the Strait of Hormuz or face strikes on power plants. OpenAI's CFO raised concerns about the company's 2026 IPO timeline. Biotech quietly pulled in $197M while the market held its breath.
Rounds
Cambridge biotech Stipple Bio emerged from stealth with an oversubscribed $100M Series A to advance precision oncology. The Pointillist Platform identifies tumor-specific cell surface epitopes (the exact molecular shapes on cancer cells that distinguish them from healthy tissue), enabling antibody-drug conjugates that avoid the on-target/off-tumor toxicity that has plagued the ADC field. Lead candidate STP-100 is expected in clinical studies early 2027. Co-founded in 2022 by cancer biology pioneers Dr. Aaron Ring (Fred Hutch) and Dr. Aashish Manglik (UCSF). a16z's Bio+Health fund co-leading a $100M Series A for a stealth biotech is a sign that frontier AI labs are not the only ones attracting mega-rounds in life sciences.
Brain health AI company Beacon Biosignals extended its Series B to $97.2M (up from $86M in November), bringing total funding to over $132M. The company combines FDA-cleared wearable EEG technology with AI to capture and analyze real-world neural data at scale. Building the world's largest neurodiagnostic dataset across neurology, psychiatry, and sleep medicine. Co-founded by Jacob Donoghue (Harvard MD, MIT PhD in neuroscience) and Jarrett Revels. Samsung Next joining the extension signals growing interest from consumer electronics players in brain-computer interface technology.
News & Signals
Trump's Tuesday ultimatum: reopen Hormuz or 'we destroy Iran's power plants'
Easter weekend was overshadowed by the sharpest escalation signal yet. President Trump posted that if Iran does not reopen the Strait of Hormuz by 8 PM ET Tuesday (April 8), the U.S. will destroy Iran's power plants and bridges. Simultaneously, the U.S., Iran, and regional mediators were discussing terms for a potential 45-day ceasefire. Oil settled at $112/barrel (WTI) with extreme volatility. The binary outcome: either a ceasefire framework emerges by Tuesday (markets rally, oil drops, IPO window reopens) or strikes on Iranian infrastructure begin (markets crash, oil spikes past $120, global energy crisis deepens). For the startup ecosystem, Tuesday is the most consequential day since February 28. Every late-stage company with IPO ambitions, every startup with MENA exposure, and every VC fund calculating portfolio risk is watching the same clock.
OpenAI CFO raises concerns over Altman's 2026 IPO plans
The Information reported that OpenAI CFO Sarah Friar has voiced concerns about risks tied to Sam Altman's plans to take the company public as early as Q4 2026 and spend $600 billion over five years. The $600B spend plan (roughly $120B per year, more than the GDP of many countries) requires capital market access that depends on stable macro conditions, namely the kind of stable macro conditions that the Iran war is actively undermining. If OpenAI cannot IPO in 2026, it faces the challenge of sustaining a $25B+ annualized revenue business on private capital alone at an $852B valuation. The CFO-CEO tension on timing is a microcosm of the broader tension in the AI industry: the technology is moving at frontier speed, but the capital markets are moving at geopolitical speed.
Biotech emerges from AI's shadow with two $100M+ rounds
Stipple Bio's $100M Series A and Beacon Biosignals' $97.2M extended Series B represent $197M deployed into biotech/healthtech in a single weekend. This is notable because the Q1 2026 narrative was entirely about AI infrastructure, defense tech, and frontier model labs. Biotech was barely visible in the funding data. The pattern may be shifting: Anthropic acquired Coefficient Bio for $400M last week, a16z's Bio+Health fund co-led Stipple, and GV/Takeda/Samsung are backing Beacon. The thesis: AI applied to biology (drug discovery, neurodiagnostics, precision oncology) is the next category that will produce venture-scale outcomes, and the winners will be companies that own proprietary biological data, not just AI models.
North America Q1 funding surged across all stages, not just mega-rounds
Crunchbase's detailed Q1 breakdown revealed that the funding surge was not limited to the mega-rounds that dominated headlines. North American seed funding rose 30% YoY to $12B, early-stage (Series A/B) rose 38% to $40.6B, and late-stage surged 203% to $244B. Deal counts fell at seed stage (-31%) but rose at Series A/B (+12%), suggesting that investors are writing larger checks to fewer companies at seed but expanding the number of companies getting funded at growth stages. For founders, the implication is clear: raising a seed is harder than ever (fewer deals), but if you raise one, the path to Series A is better than it has been in years.
VC Mood on X
Easter Sunday's VC mood was entirely about Tuesday's deadline. The conversation split neatly into two camps. The optimists argued that the Oman-mediated ceasefire talks, combined with Trump's pattern of negotiating through public threats, meant a deal was more likely than strikes. "He did the same thing with China tariffs. Maximum pressure, then negotiate. The Hormuz deadline is leverage, not a commitment," one GP posted. These investors were advising portfolio companies to prepare for a rally scenario and be ready to announce funding rounds if markets surge.
The pessimists pointed out that Trump explicitly said "we destroy power plants and bridges," that 3,500 additional troops had already deployed, and that unlike the China tariff situation, there was an active shooting war with real casualties and destroyed infrastructure. "This is not tariff theater. AWS data centers in Bahrain are on fire. Iranian missiles are landing in Gulf states. The Strait is closed. You cannot negotiate your way out of a hot war with a public tweet deadline," another partner responded. These investors were trimming positions and extending portfolio company runways.
Stipple and Beacon's raises provided a welcome respite from the geopolitical anxiety. "Biotech is the sector that thrives when macro is uncertain," one life sciences investor noted. "Drug timelines are measured in years, not news cycles. Clinical milestones do not depend on whether the Strait of Hormuz is open. That is exactly the kind of investment thesis that works in a wartime environment." The $100M Series A for Stipple, in particular, was seen as evidence that deep-tech biotech can still command mega-rounds even when AI infrastructure dominates the conversation.
Rounds and signals sourced from SEC filings, press releases, and verified news reports. All amounts in USD unless noted. Reporting reflects information available at time of publication.